10-Q: Stryker Q3 Sales Surge, Inari Acquisition Fuels Growth

Stryker Corporation reported a 10.3% increase in net sales for the third quarter of 2025, driven by strong unit volume and the strategic acquisition of Inari Medical.

Summary

• Net sales increased 10.3% to $6,057 million for the three months ended September 30, 2025, and 11.1% to $17,945 million for the nine months.
• Adjusted diluted earnings per share (EPS) rose 11.1% to $3.19 for the three months and 12.0% to $9.16 for the nine months.
• GAAP diluted EPS increased 2.8% to $2.22 for the three months but decreased 2.4% to $6.20 for the nine months, primarily due to acquisition-related costs and impairments.
• Completed the acquisition of Inari Medical, Inc. for $4,810 million in February 2025, significantly expanding the Vascular business.
• Divested the Spinal Implants business in April 2025.
• The U.S. Department of Justice closed its inquiry into potential Foreign Corrupt Practices Act (FCPA) violations without further action.

Sentiment

Score: 8

Explanation: Stryker demonstrated strong sales and adjusted earnings growth, driven by strategic acquisitions and organic volume. The closure of a major FCPA inquiry is positive. However, GAAP earnings were impacted by acquisition-related costs and impairments, and macroeconomic risks persist.

Positives

• Strong net sales growth: 10.3% for Q3 2025 ($6,057 million) and 11.1% for 9M 2025 ($17,945 million).
• Robust adjusted diluted EPS growth: 11.1% for Q3 2025 ($3.19) and 12.0% for 9M 2025 ($9.16).
• Adjusted operating income margin increased by 90 basis points to 25.6% for Q3 2025 and 100 basis points to 24.7% for 9M 2025.
• Successful acquisition of Inari Medical, Inc. for $4,810 million, enhancing the Vascular business.
• U.S. Department of Justice closed its inquiry into potential FCPA violations without further action, removing a significant regulatory overhang.
• Orthopaedics segment operating income as a percentage of net sales increased to 28.8% for Q3 2025 and 28.7% for 9M 2025.
• MedSurg and Neurotechnology segment operating income as a percentage of net sales increased to 28.3% for 9M 2025.

Negatives

• GAAP operating income decreased 0.7% to $3,085 million for the nine months ended September 30, 2025.
• GAAP net earnings decreased 2.0% to $2,397 million for the nine months ended September 30, 2025.
• GAAP diluted EPS decreased 2.4% to $6.20 for the nine months ended September 30, 2025.
• Goodwill and other impairments significantly increased to $73 million for Q3 2025 (from $2 million in Q3 2024) and $163 million for 9M 2025 (from $21 million in 9M 2024).
• Other income (expense), net, showed a higher net expense of ($106) million for Q3 2025 (from ($42) million in Q3 2024) and ($276) million for 9M 2025 (from ($144) million in 9M 2024), primarily due to higher interest expense.
• Accumulated other comprehensive loss increased to ($766) million at September 30, 2025, from ($293) million at December 31, 2024.

Risks

• Macroeconomic and geopolitical environment, including new tariffs on imported goods from countries like China and the European Union, could increase product costs, reduce demand, and disrupt supply chains.
• Slower economic growth or recession, market volatility, and inflation pose risks that could impact business and results of operations.
• Ongoing investigations by certain regulatory authorities regarding potential Foreign Corrupt Practices Act (FCPA) violations, with unpredictable outcomes and potential financial impact.
• Product liability claims, primarily related to hip products (Rejuvenate, ABG II Modular-Neck hip stems, LFIT Anatomic CoCr V40 Femoral Heads, Wright Medical Group N.V. legacy products), could result in material adverse effects on financial position, results of operations, and cash flows. An accrual of $147 million was recorded for these matters at September 30, 2025.
• New tax laws implementing the OECD's Pillar Two global corporate minimum tax rate could increase tax expense in future periods.
• Potential credit loss in the event of nonperformance by counterparties on outstanding derivative instruments.

Future Outlook

Management anticipates continued rapid sales growth in the lower gross margin MedSurg and Neurotechnology segment, which is expected to have an unfavorable impact on gross profit as a percentage of net sales for the foreseeable future. The company is evaluating new accounting pronouncements (ASU 2025-07, 2025-06, 2025-05, 2024-03) for their potential impact on financial statements and will adopt ASU 2023-09 in the fourth quarter of 2025. New tax laws implementing the OECD's Pillar Two global corporate minimum tax rate could increase tax expense in future periods.

Management Comments

• We are driven to make healthcare better.
• We continue to monitor and evaluate the situation regarding tariffs.
• We anticipate being able to support our short-term liquidity and operating needs from a variety of sources including cash from operations, commercial paper and existing credit lines.
• We continue to have strong investment-grade short-term and long-term debt ratings that we believe should enable us to refinance our debt as needed.

Industry Context

Stryker operates as a global leader in medical technologies, with its recent acquisition of Inari Medical, Inc. demonstrating a strategic move to expand its minimally invasive product portfolio within the Vascular business. This aligns with a broader industry trend towards less invasive procedures and specialized medical devices. The divestiture of the Spinal Implants business suggests a focus on optimizing the core portfolio. The company's strong sales growth in MedSurg and Neurotechnology, particularly Vascular, indicates successful market penetration and product innovation in high-growth areas of medical technology. However, the industry faces macroeconomic headwinds, including new tariffs and global tax changes (OECD Pillar Two), which could impact supply chains and profitability.

Legal Proceedings

• Ongoing investigations by certain regulatory authorities regarding potential Foreign Corrupt Practices Act (FCPA) violations, despite the DOJ closing its inquiry.
• Product liability claims related to Rejuvenate and ABG II Modular-Neck hip stems, LFIT Anatomic CoCr V40 Femoral Heads, and certain hip products sold by Wright Medical Group N.V. prior to its 2014 divestiture.
• Accrual for product liability and other legal matters was $147 million at September 30, 2025.

Stakeholder Impact

• Shareholders: Positive impact from strong sales and adjusted EPS growth, strategic acquisitions, and the resolution of a major FCPA inquiry. Potential negative impact from increased debt, ongoing legal liabilities, and macroeconomic risks.
• Employees: Impact from share-based awards vesting upon acquisition (Inari employees) and potential workforce reductions related to structural optimization.
• Customers: Benefit from expanded product portfolio, particularly in minimally invasive treatments (Vascular business).
• Suppliers: Potential impact from tariffs and supply chain disruptions.
• Creditors: Impacted by new debt issuances and refinancing activities, though the company maintains strong investment-grade ratings.

Next Steps

• Evaluate the impact of new accounting pronouncements (ASU 2025-07, 2025-06, 2025-05, 2024-03) on consolidated financial statements.
• Adopt ASU 2023-09 (Income Taxes: Improvements to Income Tax Disclosures) in the fourth quarter of 2025.
• Continue to monitor and evaluate the macroeconomic and geopolitical environment, including tariffs and changes in trade policies.
• Address ongoing legal proceedings and product liability claims, with potential future costs.
• Refinance debt as needed, leveraging strong investment-grade ratings.

Key Dates

Recommendation

Stryker's strong top-line growth, particularly in its MedSurg and Neurotechnology segment, and robust adjusted earnings per share demonstrate solid operational performance. The strategic acquisition of Inari Medical expands its market presence in high-growth areas. While GAAP earnings were affected by acquisition-related costs and impairments, the underlying business strength and the resolution of the DOJ's FCPA inquiry are positive indicators. The company's ability to raise capital and maintain strong credit ratings further supports its growth trajectory, making it an attractive investment despite macroeconomic uncertainties and ongoing legal risks.

Keywords

Stryker, SYK, Medical Technology, MedSurg, Neurotechnology, Orthopaedics, Inari Medical, Acquisition, SEC Filing, 10-Q, Financial Results, Earnings, Sales Growth, Medical Devices, Vascular, Spinal Implants, FCPA, Tariffs, Product Liability